Ascendis Pharma A/S (NASDAQ:ASND) Receives $295.67 Average Price Target from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received a consensus recommendation of “Buy” from the nineteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation, sixteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $295.6667.

A number of brokerages have weighed in on ASND. Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday. Bank of America upped their price objective on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. Citigroup assumed coverage on shares of Ascendis Pharma A/S in a research report on Monday, May 18th. They set a “buy” rating and a $355.00 price objective for the company. Royal Bank Of Canada boosted their target price on Ascendis Pharma A/S from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Finally, Barclays upped their price target on Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th.

Insider Activity

In related news, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jean Jacques Bienaime bought 400 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was purchased at an average cost of $237.80 per share, with a total value of $95,120.00. Following the completion of the transaction, the director owned 400 shares in the company, valued at $95,120. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 40.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of hedge funds have recently added to or reduced their stakes in the business. Advisory Services Network LLC purchased a new stake in shares of Ascendis Pharma A/S during the third quarter worth $26,000. Arax Advisory Partners raised its stake in shares of Ascendis Pharma A/S by 212.2% in the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares in the last quarter. Leonteq Securities AG purchased a new position in Ascendis Pharma A/S in the fourth quarter valued at $36,000. Caitong International Asset Management Co. Ltd purchased a new position in Ascendis Pharma A/S in the fourth quarter valued at $42,000. Finally, Global Retirement Partners LLC grew its stake in Ascendis Pharma A/S by 111.9% during the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 113 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $261.00 on Monday. The firm has a market cap of $16.28 billion, a PE ratio of 30.10 and a beta of 0.37. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a 52 week low of $160.86 and a 52 week high of $282.15. The business’s fifty day simple moving average is $242.89 and its 200-day simple moving average is $232.02.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million for the quarter, compared to analyst estimates of $362.47 million. Equities analysts forecast that Ascendis Pharma A/S will post 4.63 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.